A set of microRNAs contained in melanoma-derived EVs is found to be responsible for the conversion of monocytes into MDSCs and their baseline levels in plasma clustered with the clinical efficacy of CTLA-4 or PD-1 blockade in melanoma patients (1). Here, CTLA4 is linked to melanoma.